| Bristol-Myers Squibb19 programs in shared conditions | 7 · 2 with both in phase 3Melanoma, Multiple Myeloma, Carcinoma, Non-Small-Cell Lung +4 | Nivolumab, adagrasib, izalontamab brengitecan +4 | - Regeneron Pharmaceuticals’ linvoseltamab vs elotuzumab (US & EU rights: Bristol-Myers Squibb) (Multiple Myeloma, NCT05730036)
- Regeneron Pharmaceuticals’ fianlimab in a combination vs Nivolumab (US & EU rights: Bristol-Myers Squibb) (Melanoma, NCT06246916)
- Regeneron Pharmaceuticals’ cemiplimab in a combination vs Nivolumab (US & EU rights: Bristol-Myers Squibb) (Melanoma, NCT06246916)
- and 2 more
|
| Johnson & Johnson15 programs in shared conditions | 5 · 1 with both in phase 3Multiple Myeloma, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms +2 | lazertinib, teclistamab, ramantamig +3 | - Regeneron Pharmaceuticals’ linvoseltamab vs daratumumab (most trials: Johnson & Johnson) (Immunoglobulin Light-chain Amyloidosis, NCT07901725)
- Regeneron Pharmaceuticals’ linvoseltamab vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07393282)
- Johnson & Johnson’s JNJ-95475939 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT06881251)
- and 2 more
|
| Innovent Biologics, Inc.11 programs in shared conditions | 7 · 2 with both in phase 3Multiple Myeloma, Obesity, Dermatitis, Atopic +4 | IBI3027, GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003, mazdutide | - Innovent Biologics, Inc.’s IBI356 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07330934)
- Innovent Biologics, Inc.’s IBI3027 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07754786)
- Innovent Biologics, Inc.’s IBI3002 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07399067)
|
| AbbVie17 programs in shared conditions | 7 · 1 with both in phase 3Multiple Myeloma, Carcinoma, Non-Small-Cell Lung, Dermatitis, Atopic +4 | telisotuzumab adizutecan, ABBV-1480, upadacitinib +2 | - AbbVie’s upadacitinib in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT06389136)
- AbbVie’s zumilokibart in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07027527)
- AbbVie’s APG990 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07027527)
|
| Merck & Co., Inc19 programs in shared conditions | 13 · 1 with both in phase 3Melanoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell +10 | intismeran autogene, calderasib, pembrolizumab, berahyaluronidase alfa drug combination +8 | - Regeneron Pharmaceuticals’ fianlimab in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Melanoma, NCT05608291)
- Regeneron Pharmaceuticals’ fianlimab in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Melanoma, NCT05352672)
|